{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Cleveland&page=24&state=Ohio", "query": { "state": "Ohio", "city": "Cleveland", "page": 24 }, "page_size": 10 }, "pagination": { "page": 24, "page_size": 10, "total_count": 11331, "total_pages": 1134, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Cleveland&page=25&state=Ohio&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Cleveland&page=23&state=Ohio&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-04T22:45:50.892Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06790693", "title": "A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Inavolisib", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "CDK4/6i", "type": "DRUG" }, { "name": "Letrozole", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 450, "start_date": "2025-04-09", "completion_date": "2032-02-01", "has_results": false, "last_update_posted_date": "2026-11-04", "last_synced_at": "2026-11-04T22:45:50.892Z", "location_count": 62, "location_summary": "Goodyear, Arizona • Phoenix, Arizona • Burbank, California + 50 more", "locations": [ { "city": "Goodyear", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Burbank", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "La Jolla", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06790693" }, { "nct_id": "NCT07144293", "title": "Improving Physical Ability and Cellular Senescence Elimination in HIV", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HIV", "Frailty", "Prefrail", "Aging Problems" ], "interventions": [ { "name": "Dasatinib", "type": "DRUG" }, { "name": "Quercetin", "type": "DRUG" }, { "name": "Placebo - Dasatinib", "type": "OTHER" }, { "name": "Placebo - Quercetin", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": null, "sex": "ALL", "summary": "50 Years and older" }, "enrollment_count": 82, "start_date": "2025-12-04", "completion_date": "2026-08-26", "has_results": false, "last_update_posted_date": "2026-09-15", "last_synced_at": "2026-11-04T22:45:50.892Z", "location_count": 24, "location_summary": "Los Angeles, California • San Diego, California • San Francisco, California + 18 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Torrance", "state": "California" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT07144293" }, { "nct_id": "NCT03942406", "title": "Study of BPZE1 Intranasal Pertussis Vaccine (Administered Via VaxINator(TM)), Prime + Boost, in Healthy Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Pertussis", "Whooping Cough" ], "interventions": [ { "name": "BPZE1 pertussis vaccine and VaxINator(TM) Atomization Device", "type": "COMBINATION_PRODUCT" } ], "intervention_types": [ "COMBINATION_PRODUCT" ], "sponsor": "ILiAD Biotechnologies", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "18 Years to 50 Years" }, "enrollment_count": 300, "start_date": "2019-06-15", "completion_date": "2020-06-24", "has_results": true, "last_update_posted_date": "2023-06-27", "last_synced_at": "2026-11-04T22:45:50.892Z", "location_count": 3, "location_summary": "Cleveland, Ohio • Tomball, Texas • West Jordan, Utah", "locations": [ { "city": "Cleveland", "state": "Ohio" }, { "city": "Tomball", "state": "Texas" }, { "city": "West Jordan", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT03942406" }, { "nct_id": "NCT03088033", "title": "REDUCE LAP-HF TRIAL II", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Heart Failure" ], "interventions": [ { "name": "IASD System II implant", "type": "DEVICE" }, { "name": "intra-cardiac echocardiography (ICE), or transesophageal echocardiography (TEE)", "type": "OTHER" } ], "intervention_types": [ "DEVICE", "OTHER" ], "sponsor": "Corvia Medical", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": null, "sex": "ALL", "summary": "40 Years and older" }, "enrollment_count": 608, "start_date": "2017-06-01", "completion_date": "2026-09", "has_results": false, "last_update_posted_date": "2023-02-22", "last_synced_at": "2026-11-04T22:45:50.892Z", "location_count": 44, "location_summary": "Phoenix, Arizona • Tucson, Arizona • La Jolla, California + 36 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03088033" }, { "nct_id": "NCT01185964", "title": "A Study of Olaratumab in Soft Tissue Sarcoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Sarcoma, Soft Tissue" ], "interventions": [ { "name": "Olaratumab", "type": "BIOLOGICAL" }, { "name": "doxorubicin", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 148, "start_date": "2010-10", "completion_date": "2016-04", "has_results": true, "last_update_posted_date": "2017-04-14", "last_synced_at": "2026-11-04T22:45:50.892Z", "location_count": 17, "location_summary": "Tucson, Arizona • Los Angeles, California • Aurora, Colorado + 14 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Gainesville", "state": "Florida" }, { "city": "Orlando", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01185964" }, { "nct_id": "NCT04735432", "title": "Evaluating the Pharmacodynamic Noninferiority of Efgartigimod PH20 SC Administered Subcutaneously as Compared to Efgartigimod Administered Intravenously in Patients With Generalized Myasthenia Gravis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Generalized Myasthenia Gravis" ], "interventions": [ { "name": "efgartigimod PH20 SC", "type": "BIOLOGICAL" }, { "name": "efgartigimod IV", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "argenx", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 110, "start_date": "2021-02-05", "completion_date": "2021-12-13", "has_results": true, "last_update_posted_date": "2023-02-28", "last_synced_at": "2026-11-04T22:45:50.892Z", "location_count": 14, "location_summary": "Carlsbad, California • Orange, California • Boca Raton, Florida + 11 more", "locations": [ { "city": "Carlsbad", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Boca Raton", "state": "Florida" }, { "city": "Port Charlotte", "state": "Florida" }, { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04735432" }, { "nct_id": "NCT00008398", "title": "Sargramostim in Decreasing Mucositis in Patients Receiving Radiation Therapy for Head and Neck Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Head and Neck Cancer", "Oral Complications", "Radiation Toxicity" ], "interventions": [ { "name": "sargramostim", "type": "BIOLOGICAL" }, { "name": "quality-of-life assessment", "type": "PROCEDURE" }, { "name": "radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "BIOLOGICAL", "PROCEDURE", "RADIATION" ], "sponsor": "Radiation Therapy Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": null, "start_date": "2000-10", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-11-19", "last_synced_at": "2026-11-04T22:45:50.892Z", "location_count": 217, "location_summary": "Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 167 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Huntsville", "state": "Alabama" }, { "city": "Huntsville", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Montgomery", "state": "Alabama" } ], "official_url": "https://clinicaltrials.gov/study/NCT00008398" }, { "nct_id": "NCT06631287", "title": "Randomized Double-Blind Placebo-Controlled Trial EValuating Baricitinib on PERSistent NEurologic and Cardiopulmonary Symptoms of Long COVID", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Long COVID", "Sars-CoV-2 Infection", "Coronavirus Infections", "COVID-19" ], "interventions": [ { "name": "Baricitinib", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Wes Ely", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 550, "start_date": "2024-10-21", "completion_date": "2027-07-01", "has_results": false, "last_update_posted_date": "2026-09-25", "last_synced_at": "2026-11-04T22:45:50.892Z", "location_count": 17, "location_summary": "Tucson, Arizona • Los Angeles, California • San Francisco, California + 13 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT06631287" }, { "nct_id": "NCT01943916", "title": "The PIONEER-01 Study of the Imagio Breast Imaging System", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Imagio OA/US (US and OA/US)", "type": "DEVICE" }, { "name": "Imagio gray scale ultrasound", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Seno Medical Instruments Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 2105, "start_date": "2012-12-21", "completion_date": "2015-09-09", "has_results": true, "last_update_posted_date": "2023-02-08", "last_synced_at": "2026-11-04T22:45:50.892Z", "location_count": 16, "location_summary": "Murrieta, California • Englewood, Colorado • New Haven, Connecticut + 13 more", "locations": [ { "city": "Murrieta", "state": "California" }, { "city": "Englewood", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Boca Raton", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01943916" }, { "nct_id": "NCT00190684", "title": "Long-Term, Open Label Atomoxetine Study", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Attention Deficit Hyperactivity Disorder" ], "interventions": [ { "name": "atomoxetine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Years", "maximum_age": "18 Years", "sex": "ALL", "summary": "6 Years to 18 Years" }, "enrollment_count": 1553, "start_date": "2000-08", "completion_date": "2009-10", "has_results": true, "last_update_posted_date": "2011-01-17", "last_synced_at": "2026-11-04T22:45:50.892Z", "location_count": 70, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • El Centro, California + 67 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "El Centro", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "Lafayette", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00190684" } ] }